We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Ortho Exhibits VITROS Range of Diagnostic Testing and Automation Solutions at MEDLAB Middle East 2021

By LabMedica International staff writers
Posted on 24 Jun 2021
Image: VITROS® Automation Solutions (Photo courtesy of Ortho Clinical Diagnostics)
Image: VITROS® Automation Solutions (Photo courtesy of Ortho Clinical Diagnostics)
Ortho Clinical Diagnostics (Raritan, NJ, USA) exhibited its wide range of VITROS diagnostic testing and automation solutions at MEDLAB Middle East 2021.

Ortho’s VITROS Automation Solutions presented at the event are open, flexible and scalable solutions. Versatile, effective, and reliable, VITROS Automation Solutions combined with VITROS Chemistry and Immunodiagnostic Systems delivers high-quality results, faster than VITROS Systems alone. Ortho VITROS Systems makes labs powerfully efficient with minimal training time, six-month calibration, and a 96.5% first pass yield that erases the need for repeat testing. While non-VITROS systems use large, costly amounts of purified water, one VITROS System saves 160,000 liters of water per year. Ortho showcased the VITROS XT Systems that embrace DIGITAL CHEMISTRY™ and are powered by a new digital reflectometer, connecting lab ecosystems better than ever before, driving efficiency, productivity and improving the quality of care provided to patients.

Ortho also highlighted its COVID-19 testing solutions at the event, including the VITROS antibody assays for COVID-19. This included VITROS Anti-SARS-COV-2 Total test which qualitatively measures total (ALL) antibodies to the SARS-CoV-2 virus (IgG, IgM, IgA and other isotypes) and therefore has the widest clinical utility to measure immune response. This antibody test can be used to aid in the diagnosis of acute or past infection in conjunction with other laboratory tests and or clinical information. In addition, this test may be used in population surveillance for viral exposure. Similarly, the VITROS Anti-SARS-COV-2 IgG test qualitatively measures IgG Antibodies to the SARS-CoV-2 virus. This antibody test has long-term applicability in identifying patients with an adaptive immune response, indicating recent or prior infection. In addition, this test may be used in population surveillance for viral exposure. In addition Ortho showcased the VITROS SARS-CoV-2 Antigen Test that produces accurate, clinically reliable results on its high-volume VITROS Systems. These analyzers normally run a broad menu of over 150 different tests from blood and body fluid samples, but now are also able to run samples derived from swabs.

Related Links:
Ortho Clinical Diagnostics

Gold Member
Aspiration System
VACUSAFE
Online QC Software
Acusera 24•7
Prefilled Tubes
Prefilled 5.0ml Tubes
HPV Test
Allplex HPV28 Detection

Channels

Clinical Chemistry

view channel
Image: Illustration of the new blood test, which uses a DNA chip to detect the tumor’s biological fingerprint (Photo courtesy of Tel Aviv University)

Blood Test on a Chip Offers Low-Cost Lung Cancer Detection Without DNA Sequencing

Lung cancer is the leading cause of cancer deaths worldwide, and screening often yields indeterminate results that prompt invasive workups. Computed tomography (CT) detects small nodules but can flag benign... Read more

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

Whole-Cell Genomic Analysis Expands the Potential of Liquid Biopsy

Liquid biopsy has expanded access to tumor genomics, but most blood-based assays rely on short, degraded fragments of cell-free circulating tumor DNA (ctDNA). Isolating intact circulating tumor cells from... Read more

Microbiology

view channel
Image: An innovative countywide program in Taiwan combines risk-based screening with decentralized community care to improve hepatitis C detection and treatment (Image Credit: iStock)

Precision Screening Helps Close Hepatitis C Diagnosis and Treatment Gaps

Hepatitis C remains a leading cause of cirrhosis and liver cancer, yet many infections go undiagnosed or untreated because health systems fail to reach those at greatest risk. Although highly effective... Read more

Pathology

view channel
Image: Through the PCCP, Proscia gains a more efficient pathway to expand Concentriq AP-Dx interoperability while maintaining regulatory oversight (Photo courtesy of Proscia)

FDA-Cleared Digital Pathology Platform Expands Interoperability for Primary Diagnosis

Rising cancer incidence is colliding with a shrinking pathologist workforce, intensifying pressure on diagnostic turnaround times in clinical laboratories. Many labs are adopting digital pathology to manage... Read more